Inotiv, Inc.
Index- P/E- EPS (ttm)-3.05 Insider Own7.00% Shs Outstand21.12M Perf Week52.54%
Market Cap342.42M Forward P/E34.15 EPS next Y0.55 Insider Trans5.86% Shs Float17.58M Perf Month-24.93%
Income-66.90M PEG- EPS next Q-0.02 Inst Own58.40% Short Float11.70% Perf Quarter-34.29%
Sales155.90M P/S2.20 EPS this Y282.00% Inst Trans4.17% Short Ratio7.10 Perf Half Y-64.72%
Book/sh27.98 P/B0.67 EPS next Y50.50% ROA4.00% Target Price69.50 Perf Year-26.30%
Cash/sh2.30 P/C8.08 EPS next 5Y- ROE7.90% 52W Range11.25 - 60.66 Perf YTD-55.76%
Dividend- P/FCF- EPS past 5Y31.80% ROI-0.30% 52W High-69.32% Beta2.28
Dividend %- Quick Ratio1.30 Sales past 5Y34.40% Gross Margin27.90% 52W Low65.41% ATR1.93
Employees541 Current Ratio1.60 Sales Q/Q370.40% Oper. Margin-3.50% RSI (14)53.33 Volatility15.28% 11.09%
OptionableYes Debt/Eq0.44 EPS Q/Q- Profit Margin10.10% Rel Volume1.93 Prev Close17.49
ShortableYes LT Debt/Eq0.43 EarningsMay 12 AMC Payout0.00% Avg Volume289.73K Price18.61
Recom1.50 SMA2011.85% SMA50-10.72% SMA200-42.63% Volume559,113 Change6.40%
Jan-31-22Initiated Lake Street Buy $60
Sep-20-21Initiated Craig Hallum Buy $45
May-16-22 11:36AM  
May-12-22 05:18PM  
May-03-22 08:04AM  
Apr-26-22 04:35PM  
Apr-25-22 02:00PM  
Mar-17-22 03:47PM  
Feb-25-22 10:33AM  
Feb-15-22 01:18PM  
Feb-10-22 04:05PM  
Jan-27-22 04:05PM  
Jan-25-22 10:00AM  
Jan-18-22 09:38AM  
Jan-10-22 08:33AM  
Jan-06-22 08:33AM  
Jan-04-22 08:33AM  
Dec-16-21 04:05PM  
Dec-15-21 12:38AM  
Dec-13-21 04:05PM  
Dec-11-21 05:38AM  
Dec-07-21 04:03PM  
Nov-29-21 04:21PM  
Nov-10-21 08:33AM  
Nov-08-21 10:56AM  
Nov-05-21 01:33PM  
Nov-04-21 12:00PM  
Nov-02-21 05:34PM  
Oct-21-21 08:05PM  
Oct-07-21 03:23PM  
Oct-06-21 01:25PM  
Oct-04-21 07:04PM  
Oct-02-21 06:03AM  
Oct-01-21 02:56PM  
Sep-30-21 05:00PM  
Sep-29-21 10:30PM  
Sep-28-21 06:15PM  
Sep-27-21 07:39PM  
Sep-26-21 11:05PM  
Sep-25-21 02:03AM  
Sep-23-21 12:08PM  
Sep-22-21 06:34PM  
Sep-21-21 05:05PM  
Aug-31-21 04:05PM  
Aug-11-21 04:05PM  
Aug-02-21 12:15PM  
Jul-30-21 06:48AM  
Jul-22-21 04:05PM  
Jul-15-21 08:33AM  
Jul-12-21 08:33AM  
Jun-28-21 08:33AM  
Jun-07-21 04:15PM  
May-27-21 08:33AM  
May-11-21 04:05PM  
May-07-21 07:59AM  
May-05-21 04:05PM  
Apr-30-21 03:40PM  
Apr-26-21 08:33AM  
Apr-23-21 11:15AM  
Apr-21-21 06:05AM  
Apr-20-21 05:16PM  
Apr-19-21 07:00AM  
Apr-16-21 08:33AM  
Apr-13-21 04:35PM  
Apr-06-21 08:33AM  
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Harkness JamesChief Operating Officer, RMSMar 15Buy19.6538,968765,63738,968Mar 16 10:47 AM
Downing Philip ASr. VP, Preclinical Srvcs.Feb 22Buy23.972,00047,94642,195Feb 23 05:22 PM
Beattie John GregoryChief Operating OfficerFeb 18Buy23.881,00023,87942,794Feb 18 05:48 PM
Pitchford William DChief HR OfficerFeb 18Buy21.123,50073,92076,174Feb 18 05:49 PM
Davis Gregory ColeDirectorFeb 18Buy22.993,75086,21437,683Feb 22 07:53 AM
Taylor BethVP- Finance & CFOFeb 18Buy23.075,000115,35883,875Feb 22 07:54 AM
Garrett MichaelChief Commercial OfficerFeb 18Buy23.501,00023,5001,000Feb 22 07:52 AM
Sagartz John EChief Strategy OfficerFeb 17Buy19.952,50649,999681,030Feb 17 05:18 PM
Davis Gregory ColeDirectorFeb 17Buy20.571,25025,71433,933Feb 22 07:53 AM
Leasure Robert Jr.President and CEOFeb 17Buy23.035,000115,131285,216Feb 17 09:42 PM
Beattie John GregoryChief Operating OfficerFeb 17Buy21.194,60097,46841,794Feb 18 05:48 PM
Beattie John GregoryChief Operating OfficerFeb 16Buy23.715,800137,52437,194Feb 18 05:48 PM
Downing Philip ASr. VP, Preclinical Srvcs.Dec 22Sale43.043,057131,57740,195Dec 30 08:40 PM
Johnson Richard AllenDirectorAug 02Option Exercise1.2925,00032,30067,683Feb 07 07:43 PM
Sagartz John EChief Strategy OfficerJun 07Buy28.701,74249,995648,524Jun 08 04:10 PM
Sagartz John EChief Strategy OfficerMay 28Buy24.782,01249,857646,782Jun 01 04:01 PM
Sagartz John EChief Strategy OfficerMay 27Buy24.005120644,770Jun 01 04:01 PM